Literature DB >> 7579063

Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis.

F Kronenberg1, P König, U Neyer, M Auinger, A Pribasnig, U Lang, J Reitinger, G Pinter, G Utermann, H Dieplinger.   

Abstract

Numerous studies have investigated lipoprotein(a) (Lp(a)) plasma concentrations in patients with ESRD, a patient group with an enormous risk for atherosclerosis. The reported differences in Lp(a) between controls and patients vary from a decrease of 49% to an increase of more than 1,000%. However, data are not consistent, mostly because of problems with statistical analysis, and only limited data are available for patients treated by continuous ambulatory peritoneal dialysis (CAPD). To estimate the significance of Lp(a) in ESRD and to demonstrate the statistical pitfalls concerning Lp(a) in case-control studies, a large multicenter study including 702 patients treated by either hemodialysis (HD) (N = 534) or CAPD (N = 168) was conducted, and results were compared with results from 256 healthy controls. Both patient groups showed significantly elevated Lp(a) levels in comparison with controls: 23.4 +/- 25.0 mg/dL (P < 0.005; HD) and 34.6 +/- 38.4 mg/dL (P < 0.0001; CAPD) versus 18.4 +/- 22.8 mg/dL (controls). CAPD patients showed significantly higher Lp(a) values than did patients treated by HD (P < 0.001). The difference between the two treatment groups possibly reflects an overproduction of Lp(a) to compensate for protein losses in CAPD patients. Both treatment groups included significantly more patients with Lp(a) values greater than the 75th percentile (25.6 mg/dL) of the control group (33.9 and 41.7% for HD and CAPD, respectively; P < 0.005). The higher Lp(a) values in patients were not explained by differences in isoform frequencies and the increase in Lp(a) was apolipoprotein(a) type specific: only patients with high-molecular-weight apolipoprotein(a) isoforms showed a significant elevation in Lp(a) levels. The increased plasma concentrations of Lp(a) may contribute to the high risk for atherosclerosis in ESRD, especially in patients treated by CAPD. Finally, it is believed that small sample sizes are responsible for the diverging results in Lp(a) literature.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579063     DOI: 10.1681/ASN.V61110

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  29 in total

1.  Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study.

Authors:  Bengt Fellström; Hallvard Holdaas; Alan G Jardine; Helen Rose; Roland Schmieder; Wim Wilpshaar; Faiez Zannad
Journal:  Kidney Blood Press Res       Date:  2007-07-11       Impact factor: 2.687

Review 2.  Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.

Authors:  Kosmas I Paraskevas
Journal:  Int Urol Nephrol       Date:  2007-12-08       Impact factor: 2.370

Review 3.  Causes and consequences of lipoprotein(a) abnormalities in kidney disease.

Authors:  Florian Kronenberg
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

Review 4.  HDL in CKD-The Devil Is in the Detail.

Authors:  Florian Kronenberg
Journal:  J Am Soc Nephrol       Date:  2018-02-22       Impact factor: 10.121

5.  Lipoprotein(a) accelerates atherosclerosis in uremic mice.

Authors:  Tanja X Pedersen; Sally P McCormick; Sotirios Tsimikas; Susanne Bro; Lars B Nielsen
Journal:  J Lipid Res       Date:  2010-06-28       Impact factor: 5.922

Review 6.  Emerging risk factors and markers of chronic kidney disease progression.

Authors:  Florian Kronenberg
Journal:  Nat Rev Nephrol       Date:  2009-12       Impact factor: 28.314

7.  Lipoprotein(a) level as a predictor of cardiovascular disease and small apoliprotein(a) isoforms in dialysis patients: assay-related differences are important.

Authors:  J Craig Longenecker; Josef Coresh; Michael J Klag; Neil R Powe; Nancy E Fink; Santica M Marcovina
Journal:  Clin Chim Acta       Date:  2008-07-18       Impact factor: 3.786

8.  Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin.

Authors:  Johannes P Schwaiger; Yoshinobu Nakada; Ramona Berberich; Katsunori Ikewaki; Benjamin Dieplinger; Emanuel Zitt; Ulrich Neyer; Hermann Salmhofer; Florian Kronenberg; Paul Koenig; Hans Dieplinger
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 8.237

Review 9.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

10.  Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis.

Authors:  Dimitrios Kirmizis; Evangelia Koutoupa; Apostolos Tsiandoulas; Aphroditi Valtopoulou; Georgios Niavis; Phani Markou; Konstantinos Barboutis
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.